In a deal that could top $2 billion, China-based Innocare Pharma Ltd. licensed the exclusive worldwide development and ...

Among severe insulin-deficient diabetes patients, 12 weeks of 100-mg, once-daily dosing of Biomea Fusion Inc.’s icovamenib ...

Lexeo Therapeutics Inc. feels like it’s in a faster lane to a BLA for its Friedreich ataxia cardiomyopathy gene therapy after ...

The 2025 Nobel Prize in Chemistry “is a story full of holes, but with enormous capacity to absorb all your attention,” Heiner Linke told reporters. “And other things.” Linke is Chair of the Nobel ...

Individuals with the inherited disorder Fanconi anemia cannot properly repair damage to their DNA, increasing risk of cancers ...

Arcus Biosciences Inc. has announced five new research programs for autoimmune and inflammatory diseases, and is targeting ...

Owlstone Medical Ltd. has been awarded up to $49.1 million in funding by the Advanced Research Projects Agency for Health ...

Even though the U.S. CDC is operating on a skeleton crew due to the partial government shutdown, it is updating its ...

The Nobel Committee announced today that it has awarded the 2025 Nobel Prize in Physiology or Medicine to three scientists ...

Kyorin Pharmaceutical Co. Ltd. is licensing Hinge Bio Inc.’s multispecific antibody-based therapy HB-2198 in Japan for ...

Beactica Therapeutics AB has held a first scientific advisory meeting with the Swedish Medical Products Agency (MPA) for BEA-17, the company’s first-in-class small-molecule targeted degrader of lysine ...

NP1, a drug developed by University of California, Los Angeles (UCLA) for heart tissue regeneration, to enter clinical trials. The monoclonal antibody blocks the production of ENPP1 protein, which was ...